Cardiovascular

DOAC of choice in stroke prevention in atrial fibrillation
Prof Tsabedze

Relevance of Non-HDL cholesterol as main target for Residual CV risk reduction (An update into new lipid modifying agents)
Prof. Alberto Zambon

Cardiovascular Risk Reduction with Lipid Lowering Agents - Arguments for Reimbursement and Dose
Prof J Snyman

Optimizing Cardiovascular Health: Benefits of Fenofibrate Long term administration
Dr Michael Farnier

Disclaimer: Any and all content of these video presentations, represents the presenters intellectual property and views and does not necessarily represent the views of CME online, Video Streaming Solutions or their suppliers

Home